摘要
目的探讨调强适形放疗与联合奈达铂+卡培他滨放化疗治疗食管癌患者的临床疗效及安全性。方法便利选取2018年10月—2019年10月就诊于该院的46例晚期食管癌患者,按随机数字表法分为两组,每组23例。A组行调强适形放疗联合奈达铂+卡培他滨放化疗方案治疗,B组行单一调强适形放疗。比较两组临床疗效、血清血管内皮生长因子(VEGF)水平及不良反应。结果A组治疗总有效率为86.96%,高于B组的60.87%,差异有统计学意义(χ^2=4.059,P=0.044);A组治疗后血清VEGF水平为(401.18±50.37)ng/L,低于B组的(458.32±53.85)ng/L,差异有统计学意义(t=3.716,P=0.001);两组放射性肺炎、反射性食管炎、骨髓抑制、胃肠道反应发生率相比,差异无统计学意义(P>0.05)。结论食管癌患者经调强适形放疗联合奈达铂+卡培他滨放化疗方案治疗可增强疗效,降低血清VEGF水平,且不会增加不良反应,安全性较高。
Objective To investigate the clinical efficacy and safety of IMRT combined with nedaplatin plus capecitabine in the treatment of esophageal cancer patients.Methods Forty-six patients with advanced esophageal cancer who were convenient admitted to the hospital from October 2018 to October 2019 were divided into two groups according to the random number table method,each with 23 cases.Group A received IMRT combined with nedaplatin plus capecitabine chemotherapy,and group B received single IMRT.The clinical efficacy,serum vascular endothelial growth factor(VEGF)levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in group A was 86.96%,which was higher than 60.87%in group B.The difference was statistically significant(χ^2=4.059,P=0.044).The serum VEGF level in group A was(401.18±50.37)ng/L,lower than(458.32±53.85)ng/L in group B,the difference was statistically significant(t=3.716,P=0.001);the incidence rates of radiation pneumonitis,reflex esophagitis,bone marrow suppression,and gastrointestinal reactions were similar in the two groups.The difference was not statistically significant(P>0.05).Conclusion Esophageal cancer patients treated with intensity-modulated conformal radiotherapy combined with nedaplatin plus capecitabine chemotherapy regimen can enhance the efficacy,reduce serum VEGF levels,and do not increase adverse reactions,and have higher safety.
作者
季海峰
JI Hai-feng(Department of Oncology,Rugao Bo’ai Hospital,Rugao,Jiangsu Province,226500 China)
出处
《中外医疗》
2020年第33期36-38,共3页
China & Foreign Medical Treatment
关键词
食管癌
调强适形放疗
奈达铂
卡培他滨
安全性
Esophageal cancer
Intensity-modulated conformal radiotherapy
Nedaplatin
Capecitabine
Safety
